

Original article

# Reference values of arterial stiffness parameters and their association with cardiovascular risk factors in the Spanish population. The EVA Study



Marta Gómez-Sánchez,<sup>a</sup> M. Carmen Patino-Alonso,<sup>a,b,c</sup> Leticia Gómez-Sánchez,<sup>a,b</sup> José I. Recio-Rodríguez,<sup>a,b,d</sup> Emiliano Rodríguez-Sánchez,<sup>a,b,e,f</sup> José A. Maderuelo-Fernández,<sup>a,b,e</sup> Luis García-Ortiz,<sup>a,b,e,g,1</sup> and Manuel A. Gómez-Marcos<sup>a,b,e,f,1,\*</sup>, on behalf of the EVA Group<sup>2</sup>

<sup>a</sup> Unidad de Investigación en Atención Primaria, Centro de Salud La Alamedilla, Salamanca, Spain

<sup>b</sup> Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

<sup>c</sup> Departamento de Estadística, Universidad de Salamanca, Salamanca, Spain

<sup>d</sup> Facultad de Ciencias de la Salud, Universidad de Burgos, Salamanca, Spain

<sup>e</sup> Servicio de Salud de Castilla y León (SACyL), Salamanca, Spain

<sup>f</sup> Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain

<sup>g</sup> Departamento de Ciencias Biomédicas y del Diagnóstico, Universidad de Salamanca, Salamanca, Spain

## Article history:

Received 8 November 2018

Accepted 10 April 2019

Available online 12 September 2019

## Keywords:

Arterial stiffness

Cardiovascular risk factors

Reference values

Spanish population

## ABSTRACT

**Introduction and objectives:** To describe, for the first time, reference values for the cardio-ankle vascular index (CAVI), brachial-ankle pulse wave velocity (BA-PWV), carotid-femoral pulse wave velocity (CF-PWV), and the central augmentation index and to establish their association with cardiovascular risk factors in the Spanish adult population aged 35 to 75 years without cardiovascular disease.

**Methods:** We conducted a cross-sectional study. Through random sampling stratified by age and sex, we included 501 participants without cardiovascular disease. The mean age was 55.9 years and 50.3% were women. The measurements were taken using the SphigmoCor and Vasera VS-1500 devices.

**Results:** Values for all measures, except those for the central augmentation index, were higher in men and increased with age and blood pressure. The mean values were as follows: CAVI,  $8.01 \pm 1.44$ ; BA-PWV,  $12.93 \pm 2.68$  m/s; CF-PWV,  $6.53 \pm 2.03$  m/s, and central augmentation index,  $26.84 \pm 12.79$ . On multiple regression analysis, mean blood pressure was associated with the 4 measures, glycated hemoglobin was associated with all measures except the central augmentation index, and body mass index showed an inverse association with CAVI. The explanatory capacity of age, sex, and mean blood pressure was 62% for BA-PWV, 49% for CF-PWV, 49%, 54% for the CAVI, and 38% for the central augmentation index. On logistic regression, hypertension was associated with the CAVI (OR = 3.45), VOP-BT (OR = 3.44), VOP-CF (OR = 3.38) and with the central augmentation index (OR = 3.73).

**Conclusions:** All arterial stiffness measures increased with age. The CAVI and CF-PWV were higher in men and the central augmentation index was higher in women, with no differences in BA-PWV.

This study is registered at ClinicalTrials.gov. Identifier NCT02623894.

© 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

## Valores de referencia de parámetros de rigidez arterial y su relación con los factores de riesgo cardiovascular en población española. Estudio EVA

## RESUMEN

**Introducción y objetivos:** Describir por primera vez valores de referencia del índice vascular corazón-tobillo (ICT), la velocidad de la onda de pulso brazo-tobillo (VOP-BT), la velocidad de la onda de pulso carótida-femoral (VOP-CF) y el índice de aumento central y establecer relación con factores de riesgo cardiovascular en población adulta española de 35 a 75 años de edad sin enfermedad cardiovascular.

**Métodos:** Estudio descriptivo transversal. Mediante muestreo aleatorio estratificado por edad y sexo, se incluyó a 501 sujetos sin enfermedad cardiovascular, con una media de edad de 55,9 años; el 50,3% eran mujeres. Mediante los dispositivos SphigmoCor y Vasera VS-1500 se realizaron las mediciones.

**Resultados:** Todas las medidas, excepto el índice de aumento central, mostraron valores mayores en varones, y aumentaron con la edad y la presión arterial. Los valores medios fueron: ICT,  $8,01 \pm 1,44$ ; VOP-BT,  $12,93 \pm 2,68$  m/s; VOP-CF,  $6,53 \pm 2,03$  m/s e índice de aumento central,  $26,84 \pm 12,79$ . En el análisis de

## Palabras clave:

Rigidez arterial

Factores de riesgo cardiovascular

Valores de referencia

Población española

## SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2019.07.004>

\* Corresponding author: Unidad de Investigación en Atención Primaria, Centro de Salud La Alamedilla, Avda. Comuneros 27-31, 37003 Salamanca, Spain.

E-mail address: [magomez@usal.es](mailto:magomez@usal.es) (M.A. Gómez-Marcos).

<sup>1</sup> These authors contributed equally to the manuscript.

<sup>2</sup> The full list of authors is shown in the annex at the end of the article.

<https://doi.org/10.1016/j.rec.2019.04.016>

1885-5857/© 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

regresión múltiple, la presión arterial media se asoció con las 4 medidas, la glucohemoglobina, con todas excepto el índice de aumento central, y el índice de masa corporal mostró asociación inversa con el ICT. Por otro lado, la capacidad explicativa de la edad, el sexo y la presión arterial media es para la VOP-BT un 62%; la VOP-CF, un 49%; el ICT, un 54% y el índice de aumento central, un 38%. En la regresión logística, la hipertensión se asoció con el ICT (OR = 3,45), la VOP-BT (OR = 3,44), la VOP-CF (OR = 3,38) y el índice de aumento central (OR = 3,73).

**Conclusiones:** Todas las medidas de rigidez aumentan con la edad; el ICT y la VOP-CF presentan valores mayores en los varones y el índice de aumento central, en las mujeres, sin diferencias en la VOP-BT.

Este estudio está registrado en ClinicalTrials.gov. Identificador: NCT02623894.

© 2019 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Abbreviations

BA-PWV: brachial-ankle pulse wave velocity  
 cAI: central augmentation index  
 CAVI: cardio-ankle vascular index  
 CF-PWV: carotid-femoral pulse wave velocity  
 CVRF: cardiovascular risk factor

## INTRODUCTION

Arterial stiffness is principally determined by age, sex, and blood pressure<sup>1</sup> and is associated with cardiovascular risk factors (CVRFs).<sup>2</sup> Meta-analyses of numerous studies have established an association between arterial stiffness and an increase in cardiovascular events.<sup>3,4</sup> Increased arterial stiffness precedes changes in vessel structure, and its early detection therefore has an important role to play in disease prevention.<sup>5</sup>

Arterial stiffness can be assessed noninvasively from several parameters. The gold standard measure is carotid-femoral pulse wave velocity (CF-PWV), which is determined by tonometry.<sup>2</sup> CF-PWV is dependent on blood pressure at the time of measurement and reflects arterial stiffness in the descending aorta, the iliac arteries, the first segment of the femorals, the brachiocephalic trunk, and the common carotid artery but does not evaluate the ascending aorta.<sup>6</sup> Brachial-ankle pulse wave velocity (BA-PWV) is measured by oscilometry and estimates peripheral arterial stiffness in the tibial and brachial arteries.<sup>7</sup>

Another oscilometry-based measure is the cardio-ankle vascular index (CAVI), which analyzes arterial stiffness in the aorta (including the ascending aorta) and the iliac, femoral, and tibial arteries; CAVI is independent of blood pressure at the time of measurement.<sup>8</sup> Lastly, the central augmentation index (cAI) tracks the increase in central blood pressure caused by wave reflections returning from the peripheral arteries; cAI is the most widely used surrogate of arterial wave reflections, and some authors regard it as a measure of systemic arterial stiffness.<sup>9</sup>

Several studies in recent years have reported mean values for these parameters stratified by age and sex. For example, CF-PWV has been assessed in a European population<sup>6</sup> and a Spanish population older than 65 years.<sup>10</sup> BA-PWV has been assessed in an Asian population,<sup>11</sup> CAVI has been assessed in populations from Japan<sup>12</sup> and the Mediterranean region,<sup>13</sup> and cAI has been explored in a Korean population.<sup>14</sup> Other studies have assessed the association between arterial stiffness and CVRFs. However, no previous study has addressed these 2 questions in a single population without cardiovascular disease.

The current study examined arterial stiffness in a population of Spanish adults between the ages of 35 and 75 years and with no overt cardiovascular disease. The study had 3 objectives: *a*) to provide the first definition of reference values for CAVI, BA-PWV,

CF-PWV, and cAI in this population; *b*) to study the relationship between arterial stiffness measures and CVRFs; and *c*) to analyze sex differences.

## METHODS

### Study design

We conducted a cross-sectional descriptive study of participants in the EVA study (Association between different risk factors and vascular accelerated ageing study) (NCT02623894).<sup>17</sup>

### Study population

Participants were recruited from an urban population of 43 946 individuals assigned to 5 health care centers. A total of 501 participants between the ages of 35 and 75 years was selected by a random sampling stratified by age group (35–44, 45–54, 55–64, 65–74, and >75 years) and sex, with approximately 100 participants (50 men and 50 women) in each age group. The study population was selected between June 2016 and November 2017. The inclusion criteria were age between 35 and 75 years and provision of written informed consent. The exclusion criteria were end-stage disease; inability to attend the assigned health care centers; a history of cardiovascular disease; a glomerular filtration rate < 30 mL/min/1.73 m<sup>2</sup>; chronic inflammatory disease or an acute inflammatory process in the preceding 3 months; or treatment with estrogens, testosterone, or growth hormone.

Accepting an alpha risk of 0.05, the 501-participant sample size allowed us to estimate the arterial stiffness parameters with the following levels of precision: CAVI,  $\pm 0.125$  units (standard deviation  $\pm 1.44$ ); BA-PWV,  $\pm 0.235$  m/s (standard deviation  $\pm 2.68$  m/s); CF-PWV,  $\pm 0.175$  m/s (standard deviation  $\pm 2.03$  m/s); and cAI,  $\pm 1.125\%$  (standard deviation  $\pm 12.70\%$ ).

### Variables and measurement devices

The variables collected and tests performed are described in detail in the EVA study protocol.<sup>17</sup> Prior training was provided to nursing staff performing the tests and conducting the questionnaires. The measurement of CVRFs is described in detail in the Appendix of the supplementary data.

### Arterial stiffness parameters

#### Central augmentation index and carotid-femoral pulse wave velocity

These parameters were measured with a SphygmoCor device (AtCorMedical Pty Ltd; West Ryde, Australia). For the measurement of CF-PWV, patients were seated with their dominant arm supported on a rigid surface. Central and peripheral blood pressure

readings were obtained with a sensor located over the radial artery, and pulse wave morphology in the aorta and cAI were estimated with the following formula: central blood pressure increase  $\times 100$  / pulse pressure, adjusted to a 75 bpm heart rate. For the analysis of carotid and femoral pulse waves, patients were placed in a supine position, the delay relative to the electrocardiogram wave was estimated, and PWV was calculated. Distances were measured with a measuring tape from the sternal notch to the positions of the sensors over the carotid and femoral arteries and were multiplied by 0.8.<sup>18</sup>

#### Cardio-ankle vascular index and brachial-ankle pulse wave velocity

CAVI and BA-PWV were measured with a VaSera VS-1500 vascular screening system (FukudaDenshi) according to the manufacturer's instructions.<sup>19</sup> Participants were asked not to smoke or consume caffeine for 1 hour before the examination and to lie down for at least 10 minutes before the measurement. Cuffs were fitted to the size of the arms and ankles. Electrodes were attached to the 2 arms and ankles, and a microphone was fixed with double-sided tape over the sternum in the second intercostal space. CAVI measurements were considered valid only when obtained during at least 3 consecutive heartbeats.<sup>8</sup> CAVI was calculated with the following equation:

$$CAVI = a[(2\rho/\Delta P)\ln(Ps/Pd)PWV2] + b$$

where PWV is the value measured from the aortic valve orifice to the ankle; Ps and Pd are the systolic and diastolic blood pressure;  $\Delta P$  is the change in blood pressure; and  $\rho$  is the blood density.<sup>8</sup>

BA-PWV was calculated with the following equation:

$$BA-PWV = (0.5934 \times \text{height}(cm) + 144724) / TBA$$


where TBA is the time interval between the brachial and ankle pulse waves.<sup>8</sup>

For all the parameters analyzed, a higher value indicates greater arterial stiffness.

#### Statistical analysis

Continuous variables are expressed as mean  $\pm$  standard deviation, and for the arterial stiffness parameters we calculated the 5<sup>th</sup>, 10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, 90<sup>th</sup>, and 95<sup>th</sup> percentiles. Categorical variables are presented as number and percentage. Comparisons of means between 2 independent categories were made by the Student *t* test, and proportions were compared by the chi-square test. Comparisons of means between more than 2 groups were made by the ANOVA and ANCOVA tests, using the Bonferroni correction for posthoc comparisons.

Associations among arterial stiffness parameters and other variables were studied with a set of 3 multiple regression analyses. a) One analysis used 4 models to calculate the per-decade increase in arterial stiffness. The dependent variables were CAVI, BA-PWV,



**Figure 1.** Age-stratified median values of arterial stiffness parameters and 5th, 10th, 90th, and 95th percentiles in the total study population and by sex. BA-PWV, brachial-ankle pulse wave velocity; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity.

CF-PWV, and cAI; the independent variable was the age decade; and the adjustment variables were mean blood pressure, glycohemoglobin, body mass index, atherogenic index, and the number of smoking years. *b*) Another analysis examined the association between CAVI, BA-PWV, CF-PWV, and cAI. Explicit variables were mean blood pressure, glycohemoglobin, body mass index, atherogenic index, and the number of smoking years, and the adjustment variables were age and pharmacotherapy with hypotensive, hypoglycemic, and hypolipidemic drugs. *c*) For each arterial stiffness parameter, a set of 7 equations was derived by successively incorporating the following variables: age, sex, mean blood pressure, smoking, diabetes mellitus, dyslipidemia, and obesity.

A set of 4 logistic regression models was developed using CAVI, BA-PWV, CF-PWV, and cAI as response variables. The independent variables were hypertension, diabetes mellitus, obesity, and dyslipidemia. The adjustment variables were age; pharmacotherapy with hypotensive, hypoglycemic, and hypolipidemic drugs; and the analyzed CVRFs. Cut-off values for defining arterial stiffness as pathological were the values closest to the 75<sup>th</sup> percentile in each variable (CAVI  $\geq$  9; BA-PWV  $\geq$  14.50 m/s, CF-PWV  $\geq$  7.5 m/s, and cAI  $\geq$  35). For CVRFs, 1 = presence and 0 = absence.

All analyses were conducted with the statistical package SPSS for Windows, version 23.0 (IBM Corp; Armonk, New York, United States). The limit of statistical significance in the hypothesis comparison was established at an  $\alpha$  risk = 0.05.

### Ethics statement

All participants were informed about the study and gave written informed consent before inclusion. The study was approved on May 4, 2015 by the Salamanca health area ethics committee. The study was conducted in accordance with the recommendations of the Helsinki declaration.<sup>20</sup>

## RESULTS

### Study population

The study flow chart shows the reference population (43 946), the included participants and the excluded population, and the reasons for exclusion by age group and sex (Figure 1 in

**Table 1**  
General characteristics of 35-75-year-old study participants in the total sample and by sex

Variables	Total (N = 501)	Men (n = 249)	Women (n = 252)	P
Age, y	55.90 $\pm$ 14.24	55.95 $\pm$ 14.30	55.85 $\pm$ 14.19	.935
Smokers	90 (18.00)	49 (19.70)	41.00 (16.30)	.190
Height, cm	165.11 $\pm$ 9.68	171.60 $\pm$ 7.46	158.70 $\pm$ 6.98	< .001
Weight, kg	72.41 $\pm$ 13.61	79.22 $\pm$ 11.75	65.67 $\pm$ 11.87	< .001
Waist circumference, cm	93.33 $\pm$ 12.01	98.76 $\pm$ 9.65	87.93 $\pm$ 11.70	< .001
BMI	26.52 $\pm$ 4.23	26.90 $\pm$ 4.08	26.14 $\pm$ 4.79	.044
BMI $\geq$ 30	94 (18.80)	42 (16.90)	52 (20.60)	.304
SBP, mmHg	120.69 $\pm$ 23.13	126.47 $\pm$ 19.52	114.99 $\pm$ 24.96	< .001
DBP, mmHg	75.53 $\pm$ 10.10	77.40 $\pm$ 9.37	73.67 $\pm$ 10.46	< .001
MBP, mmHg	87.44 $\pm$ 13.21	93.76 $\pm$ 11.13	80.58 $\pm$ 12.61	< .001
Hypertension	147 (29.34)	82 (32.93)	65 (25.79)	< .001
Antihypertensive drugs	96 (19.20)	50 (20.10)	46 (18.30)	.650
Total cholesterol, mg/dL	194.76 $\pm$ 32.50	192.61 $\pm$ 32.26	196.88 $\pm$ 32.64	.142
LDL-C, mg/dL	115.51 $\pm$ 29.37	117.43 $\pm$ 14.12	113.61 $\pm$ 28.54	.148
HDL-C, mg/dL	58.75 $\pm$ 16.16	53.19 $\pm$ 14.12	64.22 $\pm$ 28.54	< .001
Triglycerides, mg/dL	103.06 $\pm$ 53.19	112.28 $\pm$ 54.39	93.95 $\pm$ 50.50	< .001
Atherogenic index	3.54 $\pm$ 1.07	3.84 $\pm$ 1.15	3.24 $\pm$ 0.93	< .001
Dyslipidemia	191 (38.10)	95 (38.10)	96 (38.20)	.989
Hypolipidemic drugs	102 (20.40)	49 (19.70)	53 (21.00)	.396
Glycemia, mg/dL	88.21 $\pm$ 17.37	90.14 $\pm$ 18.71	86.30 $\pm$ 15.73	.013
HbA <sub>1c</sub> , %	5.49 $\pm$ 0.56	5.54 $\pm$ 0.63	5.44 $\pm$ 0.47	.044
Diabetes mellitus	38 (7.60)	26 (10.50)	12 (4.80)	.012
Antidiabetic drugs	35 (7.00)	23 (9.20)	12 (4.80)	.055
GFR CKD-EPI, mL/min/1.73m <sup>2</sup>	93.17 $\pm$ 16.38	91.54 $\pm$ 16.42	94.77 $\pm$ 16.21	.027
CAVI	8.01 $\pm$ 1.44	8.13 $\pm$ 1.49	7.87 $\pm$ 1.39	.043
CAVI $\geq$ 9	123 (24.60)	79 (31.70)	44 (17.50)	< .001
BA-PWV, m/s	12.93 $\pm$ 2.68	13.16 $\pm$ 2.46	12.71 $\pm$ 2.86	.064
BA-PWV $\geq$ 14.5 m/s	122 (24.60)	67 (31.70)	55 (17.50)	.116
CF-PWV, m/s	6.53 $\pm$ 2.03	6.86 $\pm$ 2.20	6.21 $\pm$ 1.79	< .001
CF-PWV $\geq$ 7.5 m/s	115 (23.30)	72 (29.60)	43 (17.20)	.001
cAI	26.84 $\pm$ 12.79	22.09 $\pm$ 13.57	31.54 $\pm$ 9.97	< .001
cAI $\geq$ 35	119 (24.00)	27 (30.10)	92 (36.90)	< .001

BA-PWV, brachial-ankle pulse wave velocity; BMI, body mass index; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HbA<sub>1c</sub>, glycohemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MBP, mean blood pressure; SBP, systolic blood pressure. Continuous variables are expressed as mean  $\pm$  standard deviation and categorical variables as no. (%). P values refer to differences between men and women.

**Table 2**

Differences in vascular function parameters between individuals with and without cardiovascular risk factors in the total sample and by sex

	Total, mean (95%CI)	P	Men, mean (95%CI)	P	Women, mean (95%CI)	P
<b>CAVI</b>						
Hypertension	1.26 (1.01-1.52)	<.001	1.31 (0.95-1.67)	<.001	1.17 (1.79-1.56)	<.001
Diabetes mellitus	1.29 (0.89-1.69)	<.001	1.38 (0.94-1.81)	<.001	0.99 (0.05-1.93)	<.031
Obesity	-0.03 (-0.57 to 0.32)	.957	0.01 (-0.53 to 0.54)	.984	-0.03 (-0.47 to 0.42)	.908
Dyslipidemia	0.67 (0.41-0.93)	<.001	0.46 (0.08-0.84)	.018	0.87 (0.52-1.23)	<.001
Smoking	-0.27 (-0.57 to -0.03)	.047	-0.11 (-0.58 to 0.36)	.603	-0.49 (-0.92 to -0.06)	.026
<b>BTO-PWV</b>						
Hypertension	3.05 (2.57-3.53)	<.001	2.73 (2.10-3.36)	<.001	3.37 (2.63-4.12)	<.001
Diabetes mellitus	2.48 (1.58-3.38)	<.001	2.36 (1.41-3.30)	<.001	2.54 (0.28-4.80)	<.001
Obesity	0.93 (0.31-1.56)	.004	0.99 (0.11-1.86)	.028	0.94 (0.03-1.85)	.043
Dyslipidemia	1.57 (1.09-2.05)	<.001	0.89 (0.24-1.53)	.008	2.26 (1.55-2.96)	<.001
Smoking	-0.75 (-1.27 to -0.23)	.002	-0.26 (-0.92 to 0.40)	.433	-1.36 (-2.14 to -0.56)	<.001
<b>CF-PWV</b>						
Hypertension	3.31 (1.97-2.65)	<.001	3.30 (1.68-3.91)	<.001	2.24 (1.66-2.81)	<.001
Diabetes mellitus	2.32 (1.48-3.15)	<.001	1.94 (1.07-2.81)	<.001	2.75 (0.63-4.86)	.015
Obesity	0.68 (0.24-1.11)	.003	0.56 (-0.12 to 1.25)	0.105	0.84 (0.27-1.42)	.004
Dyslipidemia	0.77 (0.39-1.14)	<.001	0.41 (-0.17 to 0.98)	0.162	1.12 (0.66-1.59)	<.001
Smoking	-0.40 (-0.85 to 0.05)	.082	-0.09 (-0.83 to 0.64)	0.804	-0.82 (-1.23 to -0.40)	<.001
<b>cAI</b>						
Hypertension	6.38 (4.08-8.69)	<.001	7.93 (4.60-11.26)	<.001	6.38 (3.77-8.99)	<.001
Diabetes mellitus	0.46 (-2.81 to 3.80)	.781	2.22 (-0.69 to 8.33)	0.094	0.66 (-5.04-3.72)	.752
Obesity	0.607 (-1.79 to 3.01)	.618	1.65 (-1.56 to 4.86)	0.311	-1.18 (-4.28 to 1.83)	.452
Dyslipidemia	4.67 (2.44-6.90)	<.001	3.91 (0.57-7.25)	0.022	5.35 (2.95-7.75)	<.001
Smoking	1.63 (-1.42 to 4.68)	.293	1.89 (-2.38 to 6.16)	0.380	2.39 (-1.37 to 6.16)	0.208

95%CI, 95% confidence interval; cAI, central augmentation index; CAVI, cardio-ankle vascular index; BA-PWV, brachial-ankle pulse wave velocity; CF-PWV, carotid-femoral pulse wave velocity.

Data are the differences between mean values (95%CI) for vascular function parameters in study participants with and without risk factors. *P* values refer to differences between study participants with and without risk factors.

the supplementary data). The study included 501 individuals, with a mean age of  $55.90 \pm 14.24$  years; 50.3% were women.

Clinical variables in the total study population and by sex are shown in Table 1. Values for blood pressure, glycemia, triglycerides, body mass index, and waist circumference were higher in men, whereas high-density lipoprotein values were lower. Men also had a higher prevalence of hypertension and diabetes mellitus than women. Mean values of arterial stiffness parameters were as follows: CAVI,  $8.01 \pm 1.44$ ; BA-PWV,  $12.93 \pm 2.68$  m/s; CF-PWV,  $6.53 \pm 2.03$  m/s; and cAI,  $26.84 \pm 12.79$ . CAVI and CF-PWV were higher in men, whereas cAI was higher in women.

The characteristics of participants with invalid or missing arterial stiffness measures are shown in Table 1 of the supplementary data.

### Reference values for the arterial stiffness parameters analyzed

Median values of arterial stiffness parameters stratified by age and sex are shown in Figure 1 and in Table 2 of the supplementary data, and the 5<sup>th</sup>, 10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, 90<sup>th</sup>, and 95<sup>th</sup> percentiles are shown in Table 3 of the supplementary data. Mean values by age group and blood pressure category are shown in Figure 2. All the arterial stiffness measures except for cAI increased with increasing blood pressure and age.

### Relationship of arterial stiffness measures with cardiovascular risk factors and sex differences

Correlations between the analyzed arterial stiffness parameters are shown in Table 4 of the supplementary data.

In the 65–74-year age band, CAVI was higher in men than in women ( $P = .001$ ). Among study participants older than 75 years, BA-PWV was higher in women ( $P = .041$ ). In all age bands, CF-PWV was higher in men and cAI was higher in women ( $P = .001$ ) (Figure 2 of the supplementary data).

The overall CVRF-adjusted per-decade increases in arterial stiffness measures are shown in Figure 3, and the sex-stratified data are shown in Table 5 of the supplementary data.

Differences in mean arterial stiffness between individuals with or without CVRFs are summarized in Table 2. Mean values of CAVI, BA-PWV, and CF-PWV were higher in participants with hypertension, diabetes mellitus, or dyslipidemia than in those without these CVRFs; moreover, mean cAI was higher in participants with hypertension or dyslipidemia (but not diabetes mellitus). Mean BA-PWV and CF-PWV were higher in obese than in nonobese individuals. Mean CAVI and BA-PWV were lower in smokers than in nonsmokers.

Multiple regression analysis for the total study population and stratified by sex is shown in Table 3. Both in the total population and by sex, mean blood pressure was associated with all arterial stiffness parameters, glycohemoglobin was associated

**Table 3**  
Cardiovascular risk factors associated with vascular function parameters; multiple regression analysis

	Total			Men			Women		
	$\beta$ (95%CI)	P	R <sup>2</sup>	$\beta$ (95%CI)	P	R <sup>2</sup>	$\beta$ (95%CI)	P	R <sup>2</sup>
<b>CAVI</b>									
MBP	0.02 (0.01-0.02)	<.001	54%	0.02 (0.01-0.03)	.007	55%	0.01 (-0.01 to 0.02)	.014	55%
HbA <sub>1c</sub>	0.28 (0.11-0.45)	.001	54%	0.27 (0.06-0.48)	.014	55%	0.29 (0.01-0.59)	.050	55%
BMI	-0.06 (-0.08 to -0.04)	<.001	57%	-0.07 (-0.10 to -0.05)	<.001	55%	-0.05 (-0.08 to -0.01)	.014	59%
AI	0.02 (-0.06 to 0.10)	.635	54%	0.07 (-0.05 to 0.19)	.243	54%	-0.08 (-0.21 to 0.05)	.211	54%
SY	0.01 (-0.02 to 0.03)	.938	51%	-0.01 (-0.03 to 0.01)	.155	48%	0.01 (-0.01 to 0.03)	.247	47%
<b>BA-PWV</b>									
MBP	0.07 (0.05-0.08)	<.001	63%	0.07 (0.06-0.09)	<.001	60%	0.06 (0.04-0.07)	<.001	67%
HbA <sub>1c</sub>	0.55 (0.27-0.83)	<.001	64%	0.56 (0.14-0.86)	.002	60%	0.56 (0.05-1.08)	.031	68%
BMI	-0.03 (-0.06 to 0.01)	.116	64%	0.01 (-0.05 to 0.07)	.691	60%	-0.06 (-0.11 to -0.02)	.008	68%
AI	0.14 (0.01-0.26)	.040	64%	0.06 (-0.12 to 0.24)	.518	68%	0.24 (0.01-0.46)	.012	61%
SY	-0.01 (-0.02 to 0.02)	.750	62%	-0.02 (-0.04 to 0.01)	.266	58%	0.01 (-0.01 to 0.04)	.284	67%
<b>CF-PWV</b>									
MBP	0.04 (0.03-0.05)	<.001	51%	0.04 (0.03-0.05)	<.001	54%	0.03 (0.02-0.04)	<.001	53%
HbA <sub>1c</sub>	0.71 (0.46-0.95)	<.001	54%	0.53 (0.21-0.85)	.001	55%	1.01 (0.63-1.40)	<.001	54%
BMI	0.01 (-0.02 to 0.05)	.079	53%	0.04 (-0.02 to 0.09)	.220	54%	0.01 (-0.03 to 0.04)	.913	52%
AI	0.06 (-0.06 to 0.18)	.325	53%	-0.11(-0.28 to 0.06)	.210	56%	0.19 (0.027 to 0.36)	.023	54%
SY	0.01 (-0.01 to 0.02)	.674	58%	0.01 (-0.02 to 0.03)	.574	59%	-0.01 (-0.02 to 0.02)	.657	55%
<b>cAI</b>									
MBP	0.15 (0.03-0.23)	.018	23%	0.23 (0.10-0.36)	<.001	29%	0.14 (0.05-0.22)	<.002	29%
HbA <sub>1c</sub>	0.99 (-1.02 to 2.99)	.334	22%	1.82 (-1.32 to 4.96)	.256	29%	0.85 (-4.06 to 2.39)	.540	29%
BMI	-0.19 (-0.44 to 0.06)	.154	23%	-0.05 (-0.48 to 0.38)	.830	29%	-0.21 (-0.45 to 0.03)	.085	30%
AI	-0.48 (-1.41 to 0.48)	.077	23%	0.70 (-0.62 to 2.02)	.298	30%	1.02 (-0.14 to 2.17)	.084	30%
SY	0.08 (-0.06 to 0.21)	.277	17%	0.25 (0.07-0.43)	.006	27%	0.08 (-0.10 to 0.26)	.377	30%

95%CI, 95% confidence interval; AI, atherogenic index;  $\beta$ , regression coefficient; BA-PWV, brachial-ankle pulse wave velocity; BMI, body mass index; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity; HbA<sub>1c</sub>, glycohemoglobin; MBP, mean blood pressure; SY, smoking years.

Dependent variables in the multiple regression analysis were CAVI, BA-PWV, CF-PWV, and cAI, independent variables were cardiovascular risk factors (MBP, HbA<sub>1c</sub>, BMI, AI, and SY), and adjustment variables were age and pharmacotherapy with hypotensive, hypoglycemic, and hypolipidemic drugs.

with all parameters except for cAI, and body mass index showed an inverse association with CAVI. In the total study population, atherogenic index was associated with BA-PWV. In women, atherogenic index showed a direct association with BA-PWV and CF-PWV, and body mass index was inversely associated with BA-PWV. In men, smoking years showed a direct association with cAI.

Logistic regression analysis for the total study population and stratified by sex is shown in Table 4. In the total population, hypertension was associated with high values of CAVI (OR = 3.45), BA-PWV (OR = 3.44), CF-PWV (OR = 3.38), and cAI (OR = 3.73). In women, smoking was associated with high values of CAVI (OR = 3.34). In men, diabetes showed a direct association with CF-PWV (OR = 4.91).

The explanatory power of age, sex, and mean blood pressure was 62% for BA-PWV, 49% for CF-PWV, 54% for CAVI, and 38% for cAI, and there was no notable increase upon incorporation of other CVRFs into the model (Table 5).

## DISCUSSION


This is the first study to establish reference values for 4 arterial stiffness parameters in a randomly sampled Spanish population with no signs of cardiovascular disease. With the exception of cAI, the arterial stiffness parameters showed a positive association with age and blood pressure. The association with CVRFs varied

according to the parameter and sex, indicating that the influence of CVRFs on arterial stiffness parameters is nonuniform.

The CAVI values reported here are lower than those published in the REGICOR study,<sup>13</sup> probably because the prevalence of CVRFs in REGICOR was higher and also because the authors considered the highest CAVI value for analysis, rather than the mean value used here. Our mean CAVI values are also lower than those reported in a Czech population older than 50 years<sup>21</sup>; however, that study excluded people with diabetes or under treatment with hypotensive or hypolipidemic drugs. Our values are similar to those reported in populations in Japan and China<sup>12,22</sup>; however, the Japanese study excluded individuals with hypertension, diabetes, nephritis and gout, and the population was not randomly selected.

The values of BA-PWV in our cohort are lower than those reported in a Chinese population<sup>11</sup> (by 1.2 m/s and 1.5 m/s for participants in their 50s and 40s, respectively). These differences might reflect the higher prevalence of CVRFs in the Chinese study; however, BA-PWV was also higher in the Chinese subpopulation without CVRFs (by 0.8 m/s and 1.5 m/s in participants in their 50s and 40s, respectively).<sup>11</sup>

Mean CF-PWV values in our population were lower (by between 0.8 m/s and 1.5 m/s) than those reported in 13 centers in 8 European countries.<sup>6</sup> Our CF-PWV values are also lower than recently reported values from a Spanish population older than 65 years (mean age, 72.9 years; median CF-PWV in participants older than 75 years, 10.0 m/s); however, a major limitation of that



**Figure 2.** Mean arterial stiffness parameter values by age decade and blood pressure category. BP categories, optimal,  $\leq 120/80$  mmHg; normal,  $> 120/80$  mmHg and  $\leq 130/85$  mmHg; high normal,  $> 130/85$  mmHg and  $\leq 140/90$  mmHg; hypertension,  $\geq 140/90$  mmHg. BA-PWV, brachial-ankle pulse wave velocity; BP, blood pressure; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity; HT, hypertension.

study is that CF-PWV was not measured by tonometry.<sup>10</sup> Other methodological differences should also be considered. Our study analyzed a randomly selected population showing no signs of overt cardiovascular disease; moreover, all measures were recorded with the same device and using the same technique. In contrast, the European study was a retrospective analysis of several databases and excluded individuals with diabetes or taking hypoglycemic or hypolipidemic drugs.<sup>6</sup> Nevertheless, these observations appear insufficient to explain the differences with respect to our results, and these differences are likely to reflect other factors related to life style, the environment, and genetics.

Our cAI values are lower than those reported for a Korean population and were higher in women, as reported in other studies.<sup>1,14</sup> It should be noted that some authors do not regard cAI as a precise measure of arterial stiffness because it is influenced by cardiac frequency and height and declines with advancing age.<sup>23</sup>

In line with previous studies,<sup>6,13,15,16</sup> arterial stiffness measures in our population were higher in participants with diabetes or hypertension, both in the total population and by sex. We consider that the size of the differences between participants with and without CVRFs is clinically relevant for hypertension (for BA-PWV, CF-PWV, and cAI), diabetes (for BA-PWV and CF-PWV), and dyslipidemia (for cAI).

However, some of the comparisons for diabetes did not reach statistical significance, probably due to a lack of statistical power, given that the study population included only 38 people with diabetes (26 men and 12 women).

The association with obesity varied according to the arterial stiffness parameter used; for CAVI, there was an inverse correlation, as reported previously.<sup>24</sup> The sex differences found in the logistic regression may reflect the influence of estrogens, as well as differences in height and body-fat distribution<sup>25</sup> and

inflammatory factors.<sup>26</sup> Obesity showed a positive correlation with CF-PWV, and while this trend did not reach statistical significance, it is in line with the results of the Whitehall II study.<sup>27</sup>

Zhao et al.<sup>28</sup> found an independent association between cholesterol and CF-PWV, whereas in our analysis atherogenic index showed an association only with CF-PWV in women, in line with the results published by Elosua et al.<sup>13</sup> Nevertheless, other studies have shown no association between these variables.<sup>6,11</sup> The independence of arterial stiffness from dyslipidemia is also supported by recently published data on CAVI.<sup>15,22</sup> Kim et al.<sup>1</sup> concluded that dyslipidemia contributes to increased arterial stiffness in women but not in men, and proposed that arteries in women may be more vulnerable to CVRFs than those in men. These discrepancies in the data may be related to differences in the definition of dyslipidemia used, as well as the inclusion of patients treated with hypolipidemic drugs.

Smoking is a major CVRF and one of the main causes of preventable death in developed countries. This increased risk is linked to the higher cAI in women who smoke. A lack of association between smoking and CAVI has been reported in a Mediterranean population<sup>13</sup>; however, this result may reflect the cross-sectional study design or the possible inclusion of participants who had recently stopped smoking.

In summary, the main novelty of this study is the analysis of 4 arterial stiffness parameters in the same randomly sampled population. The differences between these parameters in the study population likely reflect the fact that each analyzed arterial stiffness in distinct branches of the arterial tree, and recorded values will thus reflect the different structural properties and elasticities of the central and peripheral arteries.


The detected sex differences may be related to the higher arterial stiffness in girls before puberty, whereas in boys arterial stiffness shows a linear increase from puberty onward. Arteries

**Table 4**  
Cardiovascular risk factors associated with elevated values of vascular function parameters. Logistic regression analysis

Variable	Total		Men		Women	
	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
<b>CAVI</b>						
Hypertension	3.45 (1.63-7.26)	< .001	2.71 (1.04-7.05)	.042	4.62 (2.19-10.11)	.020
Diabetes mellitus	2.17 (0.11-43.46)	.616	1.66 (0.08-35.36)	.744	1.36 (0.10-45.59)	.823
Obesity	0.85 (0.45-1.57)	.597	1.69 (0.45-3.01)	.226	0.43 (0.15-1.26)	.138
Dyslipidemia	1.67 (0.84-3.31)	.141	1.17 (0.45-3.01)	.747	2.25 (0.77-6.55)	.138
Smoking	1.10 (0.54-2.26)	.787	0.93 (0.38-2.26)	.866	1.33 (0.36-4.92)	.668
<b>BA-PWV</b>						
Hypertension	3.44 (1.63-7.26)	< .001	2.85 (1.04-7.83)	.042	5.31 (1.37-20.46)	.015
Diabetes mellitus	2.17 (0.11-43.47)	.612	1.86 (0.06-60.34)	.725	1.78 (0.05-46.34)	.920
Obesity	0.85 (0.45-1.56)	.597	3.14 (1.26-7.83)	.014	1.30 (0.50-3.46)	.599
Dyslipidemia	1.67 (0.84-3.31)	.141	1.13 (0.40-3.19)	.812	2.13 (0.75-6.05)	.157
Smoking	1.10 (0.54-2.26)	.787	1.23 (0.47-3.20)	.673	1.13 (0.31-4.05)	.856
<b>CF-PWV</b>						
Hypertension	3.38 (1.55-7.36)	.002	2.57 (0.81-8.23)	.111	6.25 (1.83-21.33)	.003
Diabetes mellitus	2.31 (0.08-68.69)	.629	4.91 (1.17-95.78)	.026	1.73 (0.07-63.05)	.085
Obesity	1.86 (0.99-3.50)	.055	1.55 (0.54-4.38)	.414	1.38 (0.54-3.57)	.501
Dyslipidemia	1.64 (0.80-3.36)	.117	1.15 (0.33-4.03)	.829	1.35 (0.46-3.91)	.586
Smoking	1.11 (0.53-2.35)	.780	0.98 (0.31-3.20)	.981	0.47 (0.11-2.02)	.311
<b>cAI</b>						
Hypertension	3.73 (1.66-8.40)	.001	1.24 (0.50-3.09)	.633	7.01 (2.25-22.11)	< .001
Diabetes mellitus	1.83 (0.93-89.55)	.076	1.11 (0.01-91.04)	.999	2.23 (0.05-71.25)	.834
Obesity	1.45 (0.74-2.86)	.283	0.84 (0.37-2.92)	.686	0.67 (0.28-1.60)	.370
Dyslipidemia	1.15 (0.52-2.53)	.736	1.06 (0.44-2.55)	.889	1.40 (0.59-3.32)	.443
Smoking	0.73 (0.31-1.75)	.491	2.19 (1.01-4.79)	.050	3.34 (1.32-8.43)	.011

95%CI, 95% confidence interval; BA-PWV, brachial-ankle pulse wave velocity; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity; OR, odds ratio.

Dependent variables in the logistic regression analysis were CAVI  $\geq 9$ , BA-PWV  $\geq 14.50$  m/s, CF-PWV  $\geq 7.5$  m/s, and cAI  $\geq 35\%$ ; independent variables were cardiovascular risk factors (hypertension, diabetes mellitus, obesity, dyslipidemia, and smoking); and adjustment variables were age, pharmacotherapy with hypotensive, hypoglycemic, and hypolipidemic drugs, and cardiovascular risk factors. For risk factors, 1 = presence and 0 = absence.



**Figure 3.** Annual increase and 95%CI by age decade in the 4 arterial stiffness parameters measured, adjusted for mean blood pressure, glycohemoglobin, body mass index, atherogenic index, and smoking years. 95%CI, 95% confidence interval; BA-PWV, brachial-ankle pulse wave velocity; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity.



**Table 5**

Regression equation for the different vascular function parameters in the total study population

Category	CAVI	R <sup>2</sup>	ΔR <sup>2</sup>
Model 1	CAVI = 3.92 + 0.073 × age	0.52	0.52
Model 2	CAVI = 3.79 + 0.073 × age + 0.26 × sex	0.53	0.01
Model 3	CAVI = 2.81 + 0.07 × age + 0.17 × sex + 0.01 × MBP	0.54	0.01
Model 4	CAVI = 2.75 + 0.07 × age + 0.17 × sex + 0.01 × MBP + 0.14 × smoking status	0.54	< 0.01
Model 5	CAVI = 2.83 + 0.07 × age + 0.14 × sex + 0.01 × MBP + 0.13 × smoking status + 0.51 × diabetes	0.54	< 0.01
Model 6	CAVI = 2.86 + 0.07 × age + 0.14 × sex + 0.01 × MBP + 0.12 × smoking status + 0.49 × diabetes + 0.11 × dyslipidemia	0.54	< 0.01
Model 7	CAVI = 2.75 + 0.07 × age + 0.12 × sex + 0.02 × MBP + 0.11 × smoking status + 0.19 × diabetes + 0.14 × dyslipidemia – 0.36 × obesity	0.55	0.01
<b>BA-PWV</b>			
Model 1	BA-PWV = 5.27 + 0.14 × age	0.53	0.53
Model 2	BA-PWV = 5.06 + 0.14 × age + 0.44 × sex	0.54	0.01
Model 3	BA-PWV = 0.15 + 0.12 × age + 0.01 × sex + 0.07 × MBP	0.62	0.08
Model 4	BA-PWV = 0.14 + 0.12 × age + 0.01 × sex + 0.07 × MBP + 0.04 × smoking status	0.62	< 0.01
Model 5	BA-PWV = 0.29 + 0.12 × age – 0.01 × sex + 0.07 × MBP + 0.03 × smoking status + 1.04 × diabetes	0.63	0.01
Model 6	BA-PWV = 0.43 + 0.11 × age – 0.04 × sex + 0.05 × MBP + 0.03 × smoking status + 0.94 × diabetes + 0.51 × dyslipidemia	0.64	0.01
Model 7	BA-PWV = 0.45 + 0.11 × age – 0.03 × sex + 0.07 × MBP + 0.03 × smoking status + 0.94 diabetes + 0.50 × dyslipidemia + 0.10 × obesity	0.64	0.01
<b>CF-PWV</b>			
Model 1	CF-PWV = 1.42 + 0.09 × age	0.41	0.41
Model 2	CF-PWV = 1.09 + 0.09 × age + 0.66 × sex	0.44	0.03
Model 3	CF-PWV = –1.75 + 0.08 × age + 0.41 × sex + 0.04 × MBP	0.49	0.06
Model 4	CF-PWV = –1.80 + 0.08 × age + 0.41 × sex + 0.04 × MBP + 0.12 × smoking status	0.49	< 0.01
Model 5	CF-PWV = –1.63 + 0.08 × age + 0.34 × sex + 0.04 × MBP + 0.13 × smoking status + 1.31 × diabetes	0.51	0.02
Model 6	CF-PWV = –1.63 + 0.08 × age + 0.34 × sex + 0.04 × MBP + 0.13 × smoking status + 1.32 × diabetes + 0.02 × dyslipidemia	0.51	< 0.01
Model 7	CF-PWV = –1.57 + 0.08 × age + 0.35 × sex + 0.04 × MBP + 0.14 × smoking status + 1.32 × diabetes – 0.04 × dyslipidemia + 0.24 × obesity	0.51	< 0.01
<b>cAI</b>			
Model 1	cAI = 3.19 + 0.42 × age	0.22	0.22
Model 2	cAI = 7.80 + 0.42 × age – 9.52 × sex	0.36	0.14
Model 3	cAI = –4.18 + 0.38 × age – 10.54 × sex + 0.17 × MBP	0.38	0.02
Model 4	cAI = –6.27 + 0.40 × age – 10.71 × sex + 0.17 × MBP + 4.73 × smoking status	0.40	0.02
Model 5	cAI = –6.54 + 0.41 × age – 10.60 × sex + 0.17 × MBP + 4.72 × smoking status – 2.06 × diabetes	0.40	< 0.01
Model 6	cAI = –6.23 + 0.40 × age – 10.56 × sex + 0.17 × MBP + 4.57 × smoking status – 2.28 × diabetes + 1.21 × dyslipidemia	0.40	< 0.01
Model 7	cAI = –6.84 + 0.40 × age – 10.69 × sex + 0.18 × MBP + 4.50 × smoking status – 2.28 × diabetes + 1.38 × dyslipidemia – 2.15 × obesity	0.40	< 0.01

ΔR<sup>2</sup>, increase in the coefficient of determination; BA-PWV, brachial-ankle pulse wave velocity; cAI, central augmentation index; CAVI, cardio-ankle vascular index; CF-PWV, carotid-femoral pulse wave velocity; MBP, mean blood pressure; R<sup>2</sup>, coefficient of determination;

Sex: 1 = man, 0 = woman. Variables added in each model: 1 age, 2 sex, 3 mean blood pressure, 4 smoking status, 5 diabetes mellitus, 6 dyslipidemia, and 7 obesity.

are thus intrinsically stiffer in women, but this is mitigated by the effects of sex steroid hormones during reproductive life. Between-population differences can be influenced not only by the prevalence of classic CVRFs and life style, but also by environmental and genetic factors. The results of the present study will help to define thresholds for the clinical identification of patients with increased arterial stiffness.

### Limitations and strengths

The main limitations of the present study are its cross-sectional design, which makes it impossible to establish causality, and the consideration of only classic CVRFs, thus providing no information about the effect of other risk factors on arterial stiffness. The study cohort was selected from an urban population, which may not be representative of the overall Spanish population. Moreover, the study population excluded individuals younger than 35 years and older than 75 years and was exclusively Caucasian. Major strengths of the study include the use of a randomly sampled population and the analysis of 4 arterial stiffness parameters, ensuring robustness to the results obtained.

### CONCLUSIONS

All 4 arterial stiffness parameters increased with age. CAVI and CF-PWV were higher in men, cAI was higher in women, and there was no sex difference in BA-PWV. These results show that the use of published values obtained in other countries and population contexts can lead to overestimation of the values in the Spanish population.

### FUNDING

This project was funded by the MICINN (*Ministerio de Ciencia, Innovación y Universidades*), the ISCIII/ERDF (*Instituto de Salud Carlos III/European Regional Development Fund*) (Red RedIAPP, RD12/0005, RD16/0007), the Castile and León regional health directorate (GRS 1193/B/15) and the research activity intensification program (INT/M/02/17 and INT/M/04/15).

### CONFLICTS OF INTEREST

None declared.

**WHAT IS KNOWN ABOUT THE TOPIC?**

- Arterial stiffness is an early indicator of atherosclerosis progression.
- Arterial stiffness can be measured by several noninvasive methods.
- The current recommended parameter in western countries is CF-PWV, but this variable depends on blood pressure at the time of measurement.

**WHAT DOES THIS STUDY ADD?**

- This is the first study to analyze 4 arterial stiffness parameters in a single sample of the Spanish population.
- Mean values of the analyzed parameters stratified by age and sex are lower than those published in other studies.
- The association of CVRFs with arterial stiffness differs according to the parameter measured and biological sex.

**APPENDIX A. EVA GROUP MEMBERS**

Manuel A. Gómez-Marcos, Luis García-Ortiz, José I. Recio-Rodríguez, Carlos Martínez-Salgado, Jesús M. Hernández-Rivas, Rogelio González-Sarmiento, Pedro L. Sánchez-Fernández, Emiliano Rodríguez-Sánchez, M. Carmen Patino-Alonso, José A. Maderuelo-Fernández, Leticia Gómez-Sánchez, Jesús González-Sánchez, Rosario Alonso-Domínguez, Carmela Rodríguez-Martín, Marta Gómez-Sánchez, Ángela de Cabo-Laso, Benigna Sánchez-Salgado, Natalia Sánchez Aguadero, Sara Mora-Simón, José Ramón González-Porras, José María Bastida-Bermejo, and Isabel Fuentes-Calvo.

**APPENDIX B. SUPPLEMENTARY DATA**

Supplementary data associated with this article can be found in the online version, at <https://doi.org/10.1016/j.rec.2019.04.016>

**REFERENCES**

1. Kim JY, Park JB, Kim DS, et al. Gender difference in arterial stiffness in a multicenter cross-sectional study: The Korean Arterial Aging Study (KAAS). *Pulse (Basel)*. 2014;2:11–17.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013;31:1281–1357.
3. Ohkuma T, Ninomiya T, Tomiyama H, et al. Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. *Hypertension*. 2017;69:1045–1052.
4. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, Ioakeimidis N, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. *Hypertension*. 2012;60:556–562.
5. Mattace-Raso FU, Van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation*. 2006;113:657–663.
6. Mattace-Raso F, Hofman A, Verwoert GC, et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values'. *Eur Heart J*. 2010;31:2338–2350.
7. Munakata M. Brachial-ankle pulse wave velocity in the measurement of arterial stiffness: recent evidence and clinical applications. *Curr Hypertens Rev*. 2014;10:49–57.
8. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. *J Atheroscler Thromb*. 2011;18:924–938.
9. Shiva Kumar P, Medina-Lezama J, Morey-Vargas O, et al. Prospective risk factors for increased central augmentation index in men and women. *Am J Hypertens*. 2015;28:121–126.
10. Sánchez-Martínez M, Cruz JJ, Graciani A, López-García E, Rodríguez-Artalejo F, Banegas JR. Pulse wave velocity and central blood pressure: normal and reference values in older people in Spain. *Rev Esp Cardiol*. 2018;71:1084–1086.
11. Yiming G, Zhou X, Lv W, et al. Reference values of brachial-ankle pulse wave velocity according to age and blood pressure in a central Asia population. *PLoS One*. 2017;12:e0171737.
12. Namekata TI, Suzuki K, Ishizuka N, Shirai K. Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. *BMC Cardiovasc Disord*. 2011;11:51.
13. Elosua-Bayés M, Martí-Lluch R, García-Gil MDM, et al. Association of classic cardiovascular risk factors and lifestyles with the cardio-ankle vascular index in a general Mediterranean population. *Rev Esp Cardiol*. 2018;71:458–465.
14. Chung JW, Lee YS, Kim JH, et al. Reference values for the augmentation index and pulse pressure in apparently healthy Korean subjects. *Korean Circ J*. 2010;40:165–171.
15. Tabara Y, Setoh K, Kawaguchi T, et al. Factors affecting longitudinal changes in cardio-ankle vascular index in a large general population: the Nagahama study. *J Hypertens*. 2018;36:1147–1153.
16. Lu YC, Lyu P, Zhu HY, et al. Brachial-ankle pulse wave velocity compared with mean arterial pressure and pulse pressure in risk stratification in a Chinese population. *J Hypertens*. 2018;36:528–536.
17. Gomez-Marcos MA, Martinez-Salgado C, Gonzalez-Sarmiento R, et al. Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. *BMJ Open*. 2016;6:e011031.
18. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445–448.
19. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). *J Atheroscler Thromb*. 2006;13:101–107.
20. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310:2191–2194.
21. Wohlfahrt P, Cifková R, Movsisyan N, et al. Reference values of cardio-ankle vascular index in a random sample of a white population. *J Hypertens*. 2017;35:2238–2244.
22. Wang H, Shirai K, Liu J, et al. Comparative study of cardio-ankle vascular index between Chinese and Japanese healthy subjects. *Clin Exp Hypertens*. 2014;36:596–601.
23. Nowak KL, Rossman MJ, Chonchol M, Seals DR. Strategies for achieving healthy vascular aging. *Hypertension*. 2018;71:389–402.
24. Gomez-Sanchez L, Garcia-Ortiz L, Patino-Alonso MC, et al. Adiposity measures and arterial stiffness in primary care: the MARK prospective observational study. *BMJ Open*. 2017;7:e016422.
25. Anoop S, Misra A, Bhardwaj S, Gulati S. High body fat and low muscle mass are associated with increased arterial stiffness in Asian Indians in North India. *J Diabetes Complications*. 2015;29:38–43.
26. Gomez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, et al. Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients. Differences by sex. *BMC Cardiovasc Disord*. 2012;12:37.
27. Brunner EJ, Shipley MJ, Ahmadi-Abhari S, et al. Adiposity, obesity, and arterial aging: longitudinal study of aortic stiffness in the Whitehall II cohort. *Hypertension*. 2015;66:294–300.
28. Zhao X, Wang H, Bo L, Zhao H, Li L, Zhou Y. Serum lipid level and lifestyles are associated with carotid femoral pulse wave velocity among adults: 4.4-year prospectively longitudinal follow-up of a clinical trial. *Clin Exp Hypertens*. 2018;40:487–494.